Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry refers to a combination of two multi-agent bowel preparation regimens, each used for gastrointestinal cleansing prior to procedures such as colonoscopy. The first regimen, "senna + gastrofin," combines senna (a stimulant laxative derived from Senna alexandrina) with Gastrofin (likely referring to Gastrografin, a contrast agent containing diatrizoate meglumine and diatrizoate sodium). Senna increases intestinal motility and fluid secretion in the colon, promoting bowel evacuation[1][5]. Gastrografin is an oral or rectal radiopaque contrast medium that also has osmotic laxative properties[3]. The second regimen, "sodium picosulfate + magnesium citrate," is a well-established oral bowel cleansing agent. Sodium picosulfate acts as a stimulant laxative by increasing peristalsis in the colon, while magnesium citrate acts as an osmotic laxative by drawing water into the intestines[6][8][10]. This combination induces watery diarrhea for effective colonic cleansing before diagnostic procedures. Both regimens are used primarily for short-term bowel preparation and not recommended for chronic use due to risks of electrolyte imbalance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on senna + gastrofin; sodium picosulfate + magnesium citrate.